Efficacy and Safety Study of an Oral Contraceptive in Healthy Females
NCT ID: NCT00206583
Last Updated: 2014-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
499 participants
INTERVENTIONAL
2005-03-31
2007-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Investigate Efficacy and Safety of a New Oral Contraceptive
NCT00185289
Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects
NCT01638910
Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters
NCT00318799
Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction
NCT01200186
Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive
NCT00185224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EV/DNG (Qlaira, BAY86-5027)
Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women and Children's Hospital, Los Angeles
Los Angeles, California, United States
Lifespan Research
Palo Alto, California, United States
Genesis Center for Clinical Research
San Diego, California, United States
Medical Center for Clinical Research
San Diego, California, United States
Harbor - UCLA Medical Center
Torrance, California, United States
Clinical Trial Center of Colorado
Castle Rock, Colorado, United States
New Age Medical Research Corp.
Miami, Florida, United States
Visions Clinical Research
Palm Springs, Florida, United States
Insignia Care for Women, P.A.
Tampa, Florida, United States
Comprehensive Clinical Trials
West Palm Beach, Florida, United States
Physicians Research Group
Indianapolis, Indiana, United States
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Women's Clinic of Lincoln, PC
Lincoln, Nebraska, United States
Women's Care Source
Morristown, New Jersey, United States
OB/GYN Health Center
Medford, Oregon, United States
Oregon Health and Science University
Portland, Oregon, United States
Clinical Research of Philadelphia, LLC
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Health System
Pittsburgh, Pennsylvania, United States
Eastern Virginia Medical School
Norfolk, Virginia, United States
Seattle Women's: Health, Research, Gynecology
Seattle, Washington, United States
Total Concept Health Care Inc.
Kitchener, Ontario, Canada
Temple Green Clinic
Waterloo, Ontario, Canada
Rhodin Recherche Clinique
Drummondville, Quebec, Canada
Centre d'étude clinique de Montréal Inc.
Montreal, Quebec, Canada
Les Gynecologues Associes
Montreal, Quebec, Canada
Clinique Recherche en Sante des Femmes Inc.
Québec, Quebec, Canada
Clinique de Gynecologie
Shawinigan, Quebec, Canada
Diex Recherche Inc.
Sherbrooke, Quebec, Canada
Clinique Médicale des Campus
Ste-Foy, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
304742
Identifier Type: OTHER
Identifier Source: secondary_id
90959
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.